Toxins 2010, 2(8), 2198-2212; doi:10.3390/toxins2082198
Article

Characterization of SNARE Cleavage Products Generated by Formulated Botulinum Neurotoxin Type-A Drug Products

Allergan, Inc., 2525 Dupont Dr, Irvine, CA 92612, USA
* Author to whom correspondence should be addressed.
Received: 9 July 2010; in revised form: 10 July 2010 / Accepted: 18 August 2010 / Published: 19 August 2010
(This article belongs to the Special Issue Toxins as Therapeutics)
PDF Full-text Download PDF Full-Text [179 KB, uploaded 19 August 2010 11:12 CEST]
Abstract: The study evaluated substrate cleavage product(s) generated by three botulinum neurotoxin serotype A (BoNT/A) medicinal drug products utilizing a novel and highly specific, light-chain activity, high-performance liquid chromatography (LCA-HPLC) method. Samples were reacted with a commercially available BoNT/A fluorescent substrate derived from the SNAP-25 sequence. Reaction products were separated by reversed-phase HPLC. The method detected an atypical cleavage pattern by one of the formulated drug products. IncobotulinumtoxinA produced two cleavage fragments rather than the single fragment typically generated by BoNT/A. Identification confirmed the secondary cleavage at a position corresponding to SNAP-25 Arg198–Ala199 (normal BoNT/A cleavage is Gln197–Arg198). Arg198–Ala199 is also the cleavage site for trypsin and serotype C toxin. Normal cleavage was observed for all other BoNT/A drug product samples, as well as 900-kD and 150-kD bulk toxin BoNT/A. The reason for this unexpected secondary cleavage pattern by one formulated BoNT/A drug product is unknown. Possible explanations include a contaminating protease and/or damage to the 150-kD type-A toxin causing nonspecific substrate recognition and subsequent cleavage uncharacteristic of type-A toxin. The BoNT/A drug products were also analyzed via the LCA-HPLC assay using a commercial BoNT/C fluorescent substrate derived from the syntaxin sequence. Cleavage of the serotype C substrate by incobotulinumtoxinA was also confirmed whilst neither of the other drug products cleaved the syntaxin substrate.
Keywords: abotulinumtoxinA; botulinum toxin; BOTOX®; Dysport®; incobotulinumtoxinA; onabotulinumtoxin A; SNAP-25; SNARE; syntaxin; Xeomin®

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Hunt, T.; Rupp, D.; Shimizu, G.; Tam, K.; Weidler, J.; Xie, J. Characterization of SNARE Cleavage Products Generated by Formulated Botulinum Neurotoxin Type-A Drug Products. Toxins 2010, 2, 2198-2212.

AMA Style

Hunt T, Rupp D, Shimizu G, Tam K, Weidler J, Xie J. Characterization of SNARE Cleavage Products Generated by Formulated Botulinum Neurotoxin Type-A Drug Products. Toxins. 2010; 2(8):2198-2212.

Chicago/Turabian Style

Hunt, Terrence; Rupp, David; Shimizu, Gary; Tam, Karen; Weidler, Julia; Xie, Jack. 2010. "Characterization of SNARE Cleavage Products Generated by Formulated Botulinum Neurotoxin Type-A Drug Products." Toxins 2, no. 8: 2198-2212.

Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert